Total Payments
$435,020
2024 Payments
$76,581
Companies
28
Transactions
818
Medicare Patients
5,692
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$296,970 (68.3%)
Consulting$77,571 (17.8%)
Travel$41,572 (9.6%)
Food & Beverage$18,651 (4.3%)
Education$256.74 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $292,445 | 184 | 67.2% |
| Consulting Fee | $77,571 | 27 | 17.8% |
| Travel and Lodging | $41,572 | 117 | 9.6% |
| Food and Beverage | $18,651 | 477 | 4.3% |
| Honoraria | $4,525 | 3 | 1.0% |
| Education | $256.74 | 10 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $145,852 | 211 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $89,644 | 166 | $0 (2024) |
| Janssen Biotech, Inc. | $68,781 | 74 | $0 (2024) |
| ABBVIE INC. | $56,390 | 93 | $0 (2024) |
| UCB, Inc. | $19,257 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $11,197 | 22 | $0 (2023) |
| Amgen Inc. | $10,670 | 52 | $0 (2024) |
| GENZYME CORPORATION | $8,933 | 14 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $5,328 | 12 | $0 (2023) |
| Horizon Therapeutics plc | $4,836 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $76,581 | 117 | Janssen Biotech, Inc. ($28,250) |
| 2023 | $101,712 | 111 | Lilly USA, LLC ($41,047) |
| 2022 | $80,942 | 126 | Lilly USA, LLC ($37,010) |
| 2021 | $19,231 | 26 | Lilly USA, LLC ($7,875) |
| 2020 | $42,590 | 136 | Lilly USA, LLC ($22,963) |
| 2019 | $81,661 | 153 | Novartis Pharmaceuticals Corporation ($61,296) |
| 2018 | $17,666 | 74 | Lilly USA, LLC ($8,404) |
| 2017 | $14,639 | 75 | AstraZeneca Pharmaceuticals LP ($5,875) |
All Payment Transactions
818 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Lilly USA, LLC | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $31.74 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Travel and Lodging | Cash or cash equivalent | $104.52 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $116.10 | General |
| Category: Inflammation | ||||||
| 12/03/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,150.00 | General |
| Category: Immunology | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,150.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $664.30 | General |
| Category: Immunology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $121.60 | General |
| Category: Immunology | ||||||
| 11/20/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $35.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $6,440.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,150.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $920.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $54.40 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $6.30 | General |
| Category: Immunology | ||||||
| 11/18/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $35.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $19.49 | General |
| 11/14/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $124.03 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Travel and Lodging | Cash or cash equivalent | $41.00 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Lilly USA, LLC | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Lilly USA, LLC | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,125.00 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 2,032 | 86,772 | $2.1M | $933,979 |
| 2022 | 32 | 2,192 | 71,669 | $1.7M | $767,995 |
| 2021 | 16 | 758 | 4,792 | $265,068 | $102,156 |
| 2020 | 11 | 710 | 10,750 | $531,583 | $196,263 |
Total Patients
5,692
Total Services
173,983
Medicare Billing
$2.0M
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 20 | 61,200 | $550,800 | $287,220 | 52.1% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 22 | 7,225 | $476,850 | $242,771 | 50.9% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 24 | 5,690 | $318,640 | $148,156 | 46.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 41 | 3,960 | $130,680 | $72,695 | 55.6% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 11 | 4,950 | $118,800 | $51,703 | 43.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 267 | 517 | $132,869 | $44,101 | 33.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 87 | 404 | $161,600 | $38,077 | 23.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 51 | 160 | $27,680 | $8,408 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $27,186 | $7,507 | 27.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 37 | 290 | $60,900 | $5,959 | 9.8% |
| 86480 | Tuberculosis test, gamma interferon | Office | 2023 | 82 | 85 | $13,430 | $5,107 | 38.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 279 | 528 | $5,280 | $4,428 | 83.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 216 | 380 | $13,300 | $3,923 | 29.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 203 | 381 | $9,906 | $2,892 | 29.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 21 | $7,266 | $2,785 | 38.3% |
| 82306 | Vitamin d-3 level | Office | 2023 | 59 | 61 | $6,161 | $1,770 | 28.7% |
| 86160 | Measurement of complement (immune system proteins), antigen, | Office | 2023 | 31 | 84 | $3,444 | $987.84 | 28.7% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 127 | 164 | $2,952 | $825.21 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 14 | $2,436 | $801.36 | 32.9% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 48 | 95 | $7,940 | $709.46 | 8.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 17 | 53 | $2,756 | $596.25 | 21.6% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2023 | 25 | 50 | $1,950 | $565.00 | 29.0% |
| 86200 | Measurement of antibody for rheumatoid arthritis assessment | Office | 2023 | 43 | 44 | $1,936 | $558.36 | 28.8% |
| 84550 | Uric acid level, blood | Office | 2023 | 31 | 54 | $810.00 | $239.22 | 29.5% |
| 84460 | Liver enzyme (sgpt), level | Office | 2023 | 23 | 34 | $646.00 | $176.46 | 27.3% |
About Dr. Kathleen Thomas, DO
Dr. Kathleen Thomas, DO is a Rheumatology healthcare provider based in Noblesville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467474031.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kathleen Thomas, DO has received a total of $435,020 in payments from pharmaceutical and medical device companies, with $76,581 received in 2024. These payments were reported across 818 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($292,445).
As a Medicare-enrolled provider, Thomas has provided services to 5,692 Medicare beneficiaries, totaling 173,983 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Noblesville, IN
- Active Since 07/24/2006
- Last Updated 11/27/2023
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1467474031
Products in Payments
- TALTZ (Drug) $92,366
- COSENTYX (Biological) $72,367
- SIMPONI ARIA (Biological) $51,463
- RINVOQ (Biological) $51,336
- OLUMIANT (Drug) $25,875
- TREMFYA (Drug) $22,435
- Bimzelx (Biological) $15,397
- KRYSTEXXA (Biological) $14,692
- COSENTYX (Drug) $4,860
- KEVZARA (Biological) $4,720
- SKYRIZI (Biological) $4,542
- NO PRODUCT DISCUSSED (Drug) $4,438
- Rasuvo (Drug) $4,179
- SAPHNELO (Biological) $3,927
- KEVZARA SARILUMAB INJECTION (Biological) $3,611
- Uloric (Drug) $2,934
- Otezla (Drug) $629.79
- Cimzia (Drug) $427.93
- XELJANZ (Drug) $381.84
- Rituxan (Biological) $294.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.